3.09
price down icon0.64%   -0.02
after-market After Hours: 3.09
loading
Maravai Lifesciences Holdings Inc stock is traded at $3.09, with a volume of 785.00K. It is down -0.64% in the last 24 hours and down -13.20% over the past month. Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
See More
Previous Close:
$3.11
Open:
$3.08
24h Volume:
785.00K
Relative Volume:
0.59
Market Cap:
$452.32M
Revenue:
$185.74M
Net Income/Loss:
$-230.76M
P/E Ratio:
-3.411
EPS:
-0.9059
Net Cash Flow:
$-70.72M
1W Performance:
+1.98%
1M Performance:
-13.20%
6M Performance:
+9.57%
1Y Performance:
+30.38%
1-Day Range:
Value
$3.07
$3.17
1-Week Range:
Value
$2.95
$3.20
52-Week Range:
Value
$1.665
$4.105

Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile

Name
Name
Maravai Lifesciences Holdings Inc
Name
Phone
(858) 546-0004
Name
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Name
Employee
435
Name
Twitter
Name
Next Earnings Date
2025-03-18
Name
Latest SEC Filings
Name
MRVI's Discussions on Twitter

Compare MRVI vs VRTX, REGN, ALNY, ARGX, INSM

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
MRVI icon
MRVI
Maravai Lifesciences Holdings Inc
3.09 455.25M 185.74M -230.76M -70.72M -0.9059
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
453.74 115.58B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
756.73 79.23B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.16 43.59B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
692.83 43.26B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
147.60 31.97B 606.42M -1.28B -997.58M -6.403

Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-26-25 Downgrade Robert W. Baird Outperform → Neutral
Dec-19-24 Initiated Guggenheim Neutral
Dec-05-24 Downgrade Goldman Neutral → Sell
Nov-14-24 Initiated Wolfe Research Peer Perform
Nov-08-24 Downgrade William Blair Outperform → Mkt Perform
Aug-28-24 Initiated Wells Fargo Overweight
Aug-13-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-10-24 Initiated Craig Hallum Buy
Dec-12-23 Upgrade BofA Securities Neutral → Buy
Aug-08-23 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
May-23-23 Downgrade Credit Suisse Outperform → Neutral
May-09-23 Downgrade Goldman Buy → Neutral
Jan-05-23 Downgrade UBS Buy → Neutral
Dec-14-22 Initiated Deutsche Bank Buy
Dec-07-22 Initiated RBC Capital Mkts Outperform
Nov-03-22 Downgrade BofA Securities Buy → Neutral
Aug-25-22 Initiated Credit Suisse Outperform
Aug-05-21 Resumed Credit Suisse Outperform
Dec-16-20 Initiated KeyBanc Capital Markets Overweight
Dec-15-20 Initiated BofA Securities Buy
Dec-15-20 Initiated Credit Suisse Outperform
Dec-15-20 Initiated Goldman Buy
Dec-15-20 Initiated Jefferies Buy
Dec-15-20 Initiated Robert W. Baird Outperform
Dec-15-20 Initiated Stifel Buy
Dec-15-20 Initiated William Blair Outperform
Dec-14-20 Initiated UBS Buy
View All

Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News

pulisher
05:17 AM

Stop Loss: What are Maravai LifeSciences Holdings Incs earnings expectationsEarnings Performance Report & Long-Term Capital Growth Strategies - baoquankhu1.vn

05:17 AM
pulisher
01:22 AM

Maravai LifeSciences stock faces ongoing volatility amid restructuring efforts and biotech sector pr - AD HOC NEWS

01:22 AM
pulisher
Mar 25, 2026

Published on: 2026-03-25 14:27:07 - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 24, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Mar 24, 2026
pulisher
Mar 23, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Investors to Connect - ACCESS Newswire

Mar 23, 2026
pulisher
Mar 19, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Mar 19, 2026
pulisher
Mar 19, 2026

Class Action Filed Against Maravai LifeSciences Holdings, Inc. (M - The National Law Review

Mar 19, 2026
pulisher
Mar 19, 2026

Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI) - MarketBeat

Mar 19, 2026
pulisher
Mar 18, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) reports Q4 loss, beats revenue estimates - MSN

Mar 18, 2026
pulisher
Mar 17, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Mar 17, 2026
pulisher
Mar 17, 2026

[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

Maravai (MRVI) General Counsel has 39,976 shares withheld for taxes - Stock Titan

Mar 17, 2026
pulisher
Mar 16, 2026

Maravai LifeSciences (NASDAQ:MRVI) Sees Large Volume IncreaseStill a Buy? - MarketBeat

Mar 16, 2026
pulisher
Mar 15, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Mar 15, 2026
pulisher
Mar 15, 2026

2026-03-15 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation | NDAQ:MRVI | Press Release - Stockhouse

Mar 15, 2026
pulisher
Mar 12, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation - ACCESS Newswire

Mar 12, 2026
pulisher
Mar 12, 2026

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Analysts - Defense World

Mar 12, 2026
pulisher
Mar 12, 2026

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Mar 12, 2026
pulisher
Mar 11, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Shareholders to Reach Out - ACCESS Newswire

Mar 11, 2026
pulisher
Mar 11, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Investors to Reach Out - ACCESS Newswire

Mar 11, 2026
pulisher
Mar 09, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Stockholders to Reach Out - ACCESS Newswire

Mar 09, 2026
pulisher
Mar 08, 2026

Maravai LifeSciences Holdings Q1 2025 Earnings Preview - MSN

Mar 08, 2026
pulisher
Mar 08, 2026

2026-03-08 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Stockholders to Reach Out | NDAQ:MRVI | Press Release - Stockhouse

Mar 08, 2026
pulisher
Mar 07, 2026

How rising interest rates impact Maravai LifeSciences Holdings Inc. stockEntry Point & Precise Trade Entry Recommendations - Naître et grandir

Mar 07, 2026
pulisher
Mar 07, 2026

How does Maravai LifeSciences Holdings Inc score in quality rankings2025 Big Picture & Fast Momentum Entry Tips - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 05, 2026

Targets Report: What are Maravai LifeSciences Holdings Incs earnings expectations2025 Price Targets & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn

Mar 05, 2026
pulisher
Mar 05, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Mar 05, 2026
pulisher
Mar 05, 2026

Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI) - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

Royce & Associates LP Has $5.06 Million Stock Position in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

First Eagle Investment Management LLC Makes New Investment in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat

Mar 05, 2026
pulisher
Mar 04, 2026

MRVI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 04, 2026
pulisher
Mar 02, 2026

MRVI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 02, 2026
pulisher
Feb 28, 2026

Maravai Lifesciences Charts Early Turnaround in 2025 - TipRanks

Feb 28, 2026
pulisher
Feb 28, 2026

Maravai LifeSciences (NASDAQ:MRVI) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat

Feb 28, 2026
pulisher
Feb 27, 2026

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Assessing a Potential 14% Upside in the Biotechnology Sector - DirectorsTalk Interviews

Feb 27, 2026
pulisher
Feb 27, 2026

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Maravai Lifesciences Holdings (MRVI) and Sarepta Therapeutics (SRPT) - The Globe and Mail

Feb 27, 2026
pulisher
Feb 26, 2026

Maravai LifeSciences (NASDAQ:MRVI) Shares Gap UpStill a Buy? - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Is Maravai LifeSciences Holdings Inc.’s ROE strong enoughMarket Growth Report & Fast Exit and Entry Trade Guides - mfd.ru

Feb 26, 2026
pulisher
Feb 26, 2026

Maravai Q4 2025 slides: return to positive EBITDA on cost cuts - Investing.com Nigeria

Feb 26, 2026
pulisher
Feb 26, 2026

Maravai LifeSciences Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 26, 2026
pulisher
Feb 26, 2026

Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call Highlights: Surpassing Revenue ... By GuruFocus - Investing.com Canada

Feb 26, 2026
pulisher
Feb 26, 2026

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace

Feb 26, 2026
pulisher
Feb 26, 2026

Maravai LifeSciences Q4 Earnings Call Highlights - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Maravai LifeSciences Holdings, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:MRVI) 2026-02-26 - Seeking Alpha

Feb 26, 2026
pulisher
Feb 26, 2026

Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call H - GuruFocus

Feb 26, 2026
pulisher
Feb 25, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Feb 25, 2026
pulisher
Feb 25, 2026

Maravai Q4 2025 slides: return to positive EBITDA on cost cuts By Investing.com - Investing.com South Africa

Feb 25, 2026
pulisher
Feb 25, 2026

Earnings call transcript: Maravai Lifesciences Q4 2025 beats EPS forecast, stock jumps 4.5% - Investing.com Canada

Feb 25, 2026
pulisher
Feb 25, 2026

MRVI: 2025 saw revenue beat, margin recovery, and strong 2026 growth and profitability guidance - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Maravai LifeSciences Holdings Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Maravai LifeSciences (NASDAQ:MRVI) Issues Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat

Feb 25, 2026

Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$27.35
price down icon 0.04%
$46.94
price down icon 0.19%
$53.57
price up icon 0.06%
$87.46
price down icon 1.48%
ONC ONC
$276.95
price down icon 2.29%
$147.60
price down icon 0.48%
Cap:     |  Volume (24h):